Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. 1998

L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
Department of Molecular Genetics, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.

Human immunodeficiency virus type 1 (HIV-1) Vif protein is required for productive HIV-1 infection of peripheral blood lymphocytes and macrophages in cell culture and for pathogenesis in the SCID-hu mouse model of HIV-1 infection. Vif inhibits the viral protease (PR)-dependent autoprocessing of truncated HIV-1 Gag-Pol precursors expressed in bacterial cells and efficiently inhibits the PR-mediated hydrolysis of peptides in cell-free systems. The obstructive activity of Vif has been assigned to the 92 amino acids residing at its N'-terminus (N-Vif). To determine the minimal Vif sequence required to inhibit PR, we synthesized overlapping peptides derived from N-Vif. These peptides were then assessed, using two in vitro and two in vivo systems: (i) inhibition of purified PR, (ii) binding of PR, (iii) inhibition of the autoprocessing of the Gag-Pol polyprotein expressed by a vaccinia virus vector, and (iv) inhibition of mature virus production in human cells. The peptides derived from two regions of N-Vif encompassing residues Tyr-30-Val-65 and Asp-78-Val-98, inhibited PR activity in both the in vitro and the in vivo assays. Thus, these peptides can be used as lead compounds to design new PR inhibitors.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011499 Protein Processing, Post-Translational Any of various enzymatically catalyzed post-translational modifications of PEPTIDES or PROTEINS in the cell of origin. These modifications include carboxylation; HYDROXYLATION; ACETYLATION; PHOSPHORYLATION; METHYLATION; GLYCOSYLATION; ubiquitination; oxidation; proteolysis; and crosslinking and result in changes in molecular weight and electrophoretic motility. Amino Acid Modification, Post-Translational,Post-Translational Modification,Post-Translational Protein Modification,Posttranslational Modification,Protein Modification, Post-Translational,Amino Acid Modification, Posttranslational,Post-Translational Amino Acid Modification,Post-Translational Modifications,Post-Translational Protein Processing,Posttranslational Amino Acid Modification,Posttranslational Modifications,Posttranslational Protein Processing,Protein Processing, Post Translational,Protein Processing, Posttranslational,Amino Acid Modification, Post Translational,Modification, Post-Translational,Modification, Post-Translational Protein,Modification, Posttranslational,Modifications, Post-Translational,Modifications, Post-Translational Protein,Modifications, Posttranslational,Post Translational Amino Acid Modification,Post Translational Modification,Post Translational Modifications,Post Translational Protein Modification,Post Translational Protein Processing,Post-Translational Protein Modifications,Processing, Post-Translational Protein,Processing, Posttranslational Protein,Protein Modification, Post Translational,Protein Modifications, Post-Translational
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015685 Fusion Proteins, gag-pol Polyprotein products of a fused portion of retroviral mRNA containing the gag and pol genes. The polyprotein is synthesized only five percent of the time since pol is out of frame with gag, and is generated by ribosomal frameshifting. gag-pol Fusion Proteins,gag-pol Protein,gag-pol Fused Protein,Fused Protein, gag-pol,Fusion Proteins, gag pol,Protein, gag-pol,Protein, gag-pol Fused,Proteins, gag-pol Fusion,gag pol Fused Protein,gag pol Fusion Proteins,gag pol Protein

Related Publications

L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
February 2003, The Journal of biological chemistry,
L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
September 2002, Journal of virology,
L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
July 2000, Journal of virology,
L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
December 2004, Virology,
L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
January 1991, FEBS letters,
L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
August 1996, Journal of virology,
L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
January 1999, Virus genes,
L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
September 1996, Journal of virology,
L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
April 1999, Journal of virology,
L Baraz, and A Friedler, and I Blumenzweig, and O Nussinuv, and N Chen, and M Steinitz, and C Gilon, and M Kotler
May 2011, Virology journal,
Copied contents to your clipboard!